Amman, Jordan Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma’s CEO, said: “Hikma has had a strong start to 2024, with continued growth and momentum across the Group. Our three businesses are performingContinue Reading
Amman, Jordan Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2023. The Group reported revenue growth of 14% (15% in constant currency) to $2.875 billion )compared to $2.517 billion in 2022). In 2023, we continued to deliverContinue Reading
into the Saudi, Jordanian and Iraqi Markets Amman, Jordan Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an exclusive licencing agreement with AFT Pharmaceuticals (AFT) for the registration and commercialization of Combogesic® IV, an intravenous, opioid-free pain relief medicine for the short term symptomaticContinue Reading
Amman, Jordan The ActivSight technology aims to provide advanced visualization in real-time, and on-demand surgical insights in the operating room. ActivSight is an easy-to-adapt module that seamlessly attaches to today’s laparoscopic, robotic systems and integrates with standard monitors providing real-time intelligence and advanced imaging — including visualization of tissue perfusionContinue Reading
to the Middle East and North Africa Amman, Jordan Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive agreement with Guardant Health, Inc., a leading precision oncology company. Through the agreement, Hikma has the exclusive rights for commercialisation and marketing of Guardant Health’s portfolio of liquid and tissueContinue Reading
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Riad Mishlawi, Chief Executive Officer of Hikma, said: “The good momentum during the first half has continued, enabling us to upgrade full year guidance in two of our three businesses.Continue Reading
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomab in 18Continue Reading
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive license agreement with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals N.V. (Cosmo). Cosmo is focused on developing and commercialising products to treat selected gastrointestinal diseases and dermatological conditions. Under the terms of the agreement, Hikma hasContinue Reading
Amman, Jordan — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa (MENA). UnderContinue Reading
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive licensing and commercialisation agreement with Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercialising precision, cell targeting therapies based on its proprietary Alluminox™ platform. Under the terms of the agreement, Hikma hasContinue Reading
